Aida Rashidi
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Aida Rashidi.
Oncotarget | 2017
Wojciech K. Panek; J. Robert Kane; Jacob S. Young; Aida Rashidi; Julius W. Kim; Deepak Kanojia; Maciej S. Lesniak
Glioblastoma is a highly aggressive malignant brain tumor with a poor prognosis and the median survival 14.6 months. Immunomodulatory proteins and oncolytic viruses represent two treatment approaches that have recently been developed for patients with glioblastoma that could extend patient survival and result in better treatment outcomes for patients with this disease. Together, these approaches could potentially augment the treatment efficacy and strength of these anti-tumor therapies. In addition to oncolytic activities, this combinatory approach introduces immunomodulation locally only where cancerous cells are present. This thereby results in the change of the tumor microenvironment from immune-suppressive to immune-vulnerable via activation of cytotoxic T cells or through the removal of glioma cells immune-suppressive capability. This review discusses the strengths and weaknesses of adenoviral oncolytic therapy, and highlights the genetic modifications that result in more effective and targeted viral agents. Additionally, the mechanism of action of immune-activating agents is described and the results of previous clinical trials utilizing these treatments in other solid tumors are reviewed. The feasibility, synergy, and limitations for treatments that combine these two approaches are outlined and areas for which more work is needed are considered.
Scientific Reports | 2017
Megan E. Muroski; Jason Miska; Alan L. Chang; Peng Zhang; Aida Rashidi; Haley Moore; Aurora Lopez-Rosas; Yu Han; Maciej S. Lesniak
Fatty acid (FA) metabolism directly influences the functional capabilities of T cells in tumor microenvironments. Thus, developing tools to interrogate FA-uptake by T cell subsets is important for understanding tumor immunosuppression. Herein, we have generated a novel FA-Qdot 605 dye conjugate with superior sensitivity and flexibility to any of the previously commercially available alternatives. For the first time, we demonstrate that this nanoparticle can be used as a specific measure of fatty acid uptake by T cells both in-vitro and in-vivo. Flow cytometric analysis shows that both the location and activation status of T cells determines their FA uptake. Additionally, CD4+ Foxp3+ regulatory T cells (Tregs) uptake FA at a higher rate than effector T cell subsets, supporting the role of FA metabolism for Treg function. Furthermore, we are able to simultaneously detect glucose and fatty acid uptake directly within the tumor microenvironment. Cumulatively, our results suggest that this novel fluorescent probe is a powerful tool to understand FA utilization within the tumor, thereby providing an unprecedented opportunity to study T cell FA metabolism in-vivo.
Molecular Therapy - Oncolytics | 2017
Julius W. Kim; Jason Miska; Jacob S. Young; Aida Rashidi; J. Robert Kane; Wojciech K. Panek; Deepak Kanojia; Yu Han; Irina V. Balyasnikova; Maciej S. Lesniak
Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer. The use of an adenovirus vector for this therapeutic modality is common, has significant clinical benefit in animals, and its efficacy has recently been linked to an anti-tumor immune response that occurs following tumor antigen presentation. Here, we analyzed the adaptive immune system’s response following viral infection by comparing replication-incompetent and replication-competent adenoviral vectors. Our findings suggest that cell death caused by replication-competent adenoviral vectors is required to induce a significant anti-tumor immune response and survival benefits in immunocompetent mice bearing intracranial glioma. We observed significant changes in the repertoire of immune cells in the brain and draining lymph nodes and significant recruitment of CD103+ dendritic cells (DCs) in response to oncolytic adenoviral therapy, suggesting the active role of the immune system in anti-tumor response. Our data suggest that the response to oncolytic virotherapy is accompanied by local and systemic immune responses and should be taken in consideration in the future design of the clinical studies evaluating oncolytic virotherapy in patients with glioblastoma multiforme (GBM).
Archive | 2018
Julius W. Kim; Katarzyna C. Pituch; Annie Xiao; Jacob S. Young; Wojciech K. Panek; Megan E. Muroski; Aida Rashidi; J. Robert Kane; Deepak Kanojia; Maciej S. Lesniak
Abstract Gene therapy is a rapidly developing treatment modality that functions on its ability to deliver genes directly to the tumor site in order to yield antitumoral effects and thus prolong patient survival. The delivery of any gene(s) requires a delivery system that either involves the direct delivery of therapeutic gene(s) to the tumor site via viral or nonviral vectors, or through carriers that express the gene(s) in the tumor site via neural stem cells, mesenchymal stem cells, or other carriers. Four basic categories of gene therapy are currently being investigated for the treatment of brain tumors: (i) prodrug activation and suicide gene therapy; (ii) immunomodulatory and cytokine-based gene therapy; (iii) brain tumor hallmark targeting therapy; and (iv) oncolytic virotherapy. Preclinical studies of gene therapy for brain tumors have led to an array of human clinical trials, demonstrated to be remarkably safe and well tolerated with encouraging therapeutic results.
Neurotherapeutics | 2018
Julius W. Kim; J. Robert Kane; Wojciech K. Panek; Jacob S. Young; Aida Rashidi; Dou Yu; Deepak Kanojia; Tanwir Hasan; Jason Miska; Miguel A. Gómez-Lim; Ilya V. Ulasov; Irina V. Balyasnikova; Atique U. Ahmed; Derek A. Wainwright; Maciej S. Lesniak
Antitumor immunotherapeutic strategies represent an especially promising set of approaches with rapid translational potential considering the dismal clinical context of high-grade gliomas. Dendritic cells (DCs) are the body’s most professional antigen-presenting cells, able to recruit and activate T cells to stimulate an adaptive immune response. In this regard, specific loading of tumor-specific antigen onto dendritic cells potentially represents one of the most advanced strategies to achieve effective antitumor immunization. In this study, we developed a DC-specific adenoviral (Ad) vector, named Ad5scFvDEC205FF, targeting the DC surface receptor, DEC205. In vitro analysis shows that 60% of DCs was infected by this vector while the infectivity of other control adenoviral vectors was less than 10%, demonstrating superior infectivity on DCs. Moreover, an average of 14% of DCs were infected by Ad5scFvDEC205FF-GFP, while less than 3% of non-DCs were infected following in vivo administration, demonstrating highly selective in vivo DC infection. Importantly, vaccination with this vehicle expressing human glioma-specific antigen, Ad5scFvDEC205FF-CMV-IE, shows a prolonged survival benefit in GL261CMV-IE-implanted murine glioma models (p < 0.0007). Furthermore, when rechallenged, cancerous cells were completely rejected. In conclusion, our novel, viral-mediated, DC-based immunization approach has the significant therapeutic potential for patients with high-grade gliomas.
Mesenchymal Stromal Cells as Tumor Stromal Modulators | 2016
Julius W. Kim; Jason Murphy; Alan L. Chang; Drew A. Spencer; Joshua Robert Kane; Deepak Kanojia; Aida Rashidi; Jacob S. Young; Maciej S. Lesniak
Modern virotherapy for the potential treatment of a wide array of human diseases, including cancer, has been investigated for its capacity to elicit therapeutic benefits by way of alterable genetic modification. And while immediate gains in the field have demonstrated pronounced efficacy in therapeutic potential, endogenous and preexisting neutralizing antibody responses hinder the delivery of these vectors. Even more so in the case of cancer therapeutic potential, limited biodistribution of such viral particles within the bulk of the tumor mass is observed. To circumvent these adversities in the delivery of a viral vector to the site of pathology, mesenchymal stem/stromal cells may be used to avoid immune stimulation with resultant vector clearance, to maximize the effective delivery potential, and to augment biodistribution ability in neoplastic tumor masses.
Cancer Immunology, Immunotherapy | 2016
Jason Miska; Aida Rashidi; Alan L. Chang; Megan E. Muroski; Yu Han; Lingjiao Zhang; Maciej S. Lesniak
Neuro-oncology | 2017
Wojciech K. Panek; Julius W. Kim; Katarzyna C. Pituch; Joshua Robert Kane; Deepak Kanojia; Alex Cordero; Jason Miska; Aida Rashidi; Jacob S. Young; Maciej S. Lesniak
Neuro-oncology | 2017
Aida Rashidi; Jason Miska; Katarzyna C. Pituch; Deepak Kanojia; Aurora Lopez-Rosas; Yu Han; Julius W. Kim; Wojciech K. Panek; Megan E. Muroski; Maciej S. Lesniak
Neuro-oncology | 2017
Jason Miska; Megan E. Muroski; Aida Rashidi; Alan Chang; Peng Zhang; Yu Han; Maciej S. Lesniak